Literature DB >> 10822303

Structural basis of DOTMA for its high intravenous transfection activity in mouse.

T Ren1, Y K Song, G Zhang, D Liu.   

Abstract

Eleven structural analogues of two known cationic lipids, N-[1-(2, 3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) and N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTAP) were synthesized and utilized to evaluate the structural characteristics of DOTMA for its high intravenous transfection activity. Using a CMV-driven expression system and luciferase gene as a reporter, the transfection activity of these analogues was evaluated in mice using tail vein injection. Results concerning the structure-activity relationship with regard to the influence of the backbone, relative position between head group and the hydrophobic chains on the backbone, linkage bonds, as well as the composition of the aliphatic chains revealed that cationic lipids which give a higher in vivo transfection activity share the following structural characteristics: (1) cationic head group and its neighboring aliphatic chain being in a 1,2-relationship on the backbone; (2) ether bond for bridging the aliphatic chains to the backbone; and (3) paired oleyl chains as the hydrophobic anchor. Cationic lipids without these structural features had lower in vivo transfection activity. These structural characteristics, however, did not significantly influence their in vitro transfection activity. The contribution that cationic lipids make to the overall in vivo transfection activity is likely to be determined by the structure of DNA/lipid complexes and by the outcome of the interaction between the DNA/lipid complexes and blood components upon intravenous administration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10822303     DOI: 10.1038/sj.gt.3301153

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  15 in total

Review 1.  Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection.

Authors:  Crispin R Dass
Journal:  J Mol Med (Berl)       Date:  2004-06-23       Impact factor: 4.599

2.  Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations.

Authors:  Xinmei Wang; Bo Yu; Wei Ren; Xiaokui Mo; Chenguang Zhou; Hongyan He; Huliang Jia; Lu Wang; Samson T Jacob; Robert J Lee; Kalpana Ghoshal; L James Lee
Journal:  J Control Release       Date:  2013-10-08       Impact factor: 9.776

3.  An amino acid-based amphoteric liposomal delivery system for systemic administration of siRNA.

Authors:  Roger C Adami; Shaguna Seth; Pierrot Harvie; Rachel Johns; Renata Fam; Kathy Fosnaugh; Tianying Zhu; Ken Farber; Michael McCutcheon; Thomas T Goodman; Yan Liu; Yan Chen; Erin Kwang; Michael V Templin; Greg Severson; Tod Brown; Narendra Vaish; Feng Chen; Patrick Charmley; Barry Polisky; Michael E Houston
Journal:  Mol Ther       Date:  2011-04-19       Impact factor: 11.454

Review 4.  Protein based therapeutic delivery agents: Contemporary developments and challenges.

Authors:  Liming Yin; Carlo Yuvienco; Jin Kim Montclare
Journal:  Biomaterials       Date:  2017-04-21       Impact factor: 12.479

5.  Ionic liquids with thioether motifs as synthetic cationic lipids for gene delivery.

Authors:  Jamie C Gaitor; Lauren M Paul; Melissa M Reardon; Taha Hmissa; Samuel Minkowicz; Matthew Regner; Yinghong Sheng; Scott F Michael; Sharon Isern; Arsalan Mirjafari
Journal:  Chem Commun (Camb)       Date:  2017-07-20       Impact factor: 6.222

6.  MicroRNA delivery by cationic lipoplexes for lung cancer therapy.

Authors:  Yun Wu; Melissa Crawford; Bo Yu; Yicheng Mao; Serge P Nana-Sinkam; L James Lee
Journal:  Mol Pharm       Date:  2011-06-20       Impact factor: 4.939

7.  ENDOCYTOSIS PATHWAYS FOR NUCLEIC ACID THERAPEUTICS.

Authors:  Amanda P Malefyt; S Patrick Walton; Christina Chan
Journal:  Nano Life       Date:  2012-09-01

8.  Trends in lipoplex physical properties dependent on cationic lipid structure, vehicle and complexation procedure do not correlate with biological activity.

Authors:  M E Ferrari; D Rusalov; J Enas; C J Wheeler
Journal:  Nucleic Acids Res       Date:  2001-04-01       Impact factor: 16.971

Review 9.  Lipid-based nanotherapeutics for siRNA delivery.

Authors:  A Schroeder; C G Levins; C Cortez; R Langer; D G Anderson
Journal:  J Intern Med       Date:  2010-01       Impact factor: 8.989

10.  Therapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung Cancer.

Authors:  Yun Wu; Melissa Crawford; Yicheng Mao; Robert J Lee; Ian C Davis; Terry S Elton; L James Lee; Serge P Nana-Sinkam
Journal:  Mol Ther Nucleic Acids       Date:  2013-04-16       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.